Stephen William Reddel

Stephen William Reddel

Auto-generated profile, based on publicly available information

Stephen William Reddel

Department of Neurology and Concord Clinical School, Concord Hospital, Australia

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RCRebecca N. Cole
Rebecca N. Cole
SRStephen W. Reddel
Stephen W. Reddel
OGOthon L. Gervásio
Othon L. Gervásio
WPWilliam D. Phillips
William D. Phillips

5 November 2011 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
NSNeil G Simon
Neil G Simon
JPJohn D Parratt
John D Parratt
MBMichael H Barnett
Michael H Barnett
MBMichael E Buckland
Michael E Buckland
RGRuta Gupta
Ruta Gupta
SRStephen W Reddel
Stephen W Reddel
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a recently described inflammatory disease of the CNS with a predilection for the hindbrain and responsive to immunotherapy. Five further cases are described with detailed pathology and long term evaluation. CLIPPERS does not represent a benign condition, and without chronic immunosuppression the disease may relapse. The radiological distribution is focused not only in the pons but also in the brachium ponti and cerebellum. Pontocerebellar atrophy occurred early, even in cases treated promptly. Significant cognitive impairment was seen in some cases and was associated with additional cerebral atrophy. The pathology included distinctive histiocytic as well as lymphocytic components and evidence of neuro-axonal injury. Additional subclinical systemic findings on investigation were identified. Relapse was associated with withdrawal of corticosteroids, and disability was least marked in cases where both the presentation and relapses were treated promptly. We propose that the title of the syndrome be amended to chronic lymphocytic inflammation with pontocerebellar perivascular enhancement responsive to steroids to more accurately reflect the distribution of the radiological findings.

23 June 2011 in Brain
Verified
Journal Article
Open access
PDF file
GNGarth Nicholson
Garth Nicholson
GLGuy M. Lenk
Guy M. Lenk
SRStephen W. Reddel
Stephen W. Reddel
AGAdrienne E. Grant
Adrienne E. Grant
CTCharles F. Towne
Charles F. Towne
MMMiriam H. Meisler
Miriam H. Meisler
Charcot–Marie–Tooth disease is a genetically heterogeneous group of motor and sensory neuropathies associated with mutations in more than 30 genes. Charcot–Marie–Tooth disease type 4J (OMIM 611228) is a recessive, potentially severe form of the disease caused by mutations of the lipid phosphatase FIG4. We provide a more complete view of the features of this disorder by describing 11 previously unreported patients with Charcot–Marie–Tooth disease type 4J. Three patients were identified from a small cohort selected for screening because of their early onset disease and progressive proximal as well as distal weakness. Eight patients were identified by large-scale exon sequencing of an unselected group of 4000 patients with Charcot–Marie–Tooth disease. In addition, 34 new FIG4 variants were detected. Ten of the new CMT4J cases have the compound heterozygous genotype FIG4I41T/null described in the original four families, while one has the novel genotype FIG4L17P/null. The population frequency of the I41T allele was found to be 0.001 by genotyping 5769 Northern European controls. Thirty four new variants of FIG4 were identified. The severity of Charcot–Marie–Tooth disease type 4J ranges from mild clinical signs to severe disability requiring the use of a wheelchair. Both mild and severe forms have been seen in patients with the same genotype. The results demonstrate that Charcot–Marie–Tooth disease type 4J is characterized by highly variable onset and severity, proximal as well as distal and asymmetric muscle weakness, electromyography demonstrating denervation in proximal and distal muscles, and frequent progression to severe amyotrophy. FIG4 mutations should be considered in Charcot–Marie–Tooth patients with these characteristics, especially if found in combination with sporadic or recessive inheritance, childhood onset and a phase of rapid progression.

1 June 2015 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
SRSudarshini Ramanathan
Sudarshini Ramanathan
DLDaman Langguth
Daman Langguth
THTodd A. Hardy
Todd A. Hardy
NGNidhi Garg
Nidhi Garg
CBChris Bundell
Chris Bundell
SRStephen W. Reddel
Stephen W. Reddel
Objective: We examined a cohort of Australian patients with statin exposure who developed a necrotizing autoimmune myopathy (NAM) associated with a novel autoantibody against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and describe the clinical and therapeutic challenges of managing these patients and an optimal therapeutic strategy. Methods: Clinical, laboratory, EMG, and histopathologic results and response to immunomodulation are reported in 6 Australian patients with previous statin exposure and antibodies targeting HMGCR. Results: All patients presented with painless proximal weakness following statin therapy, which persisted after statin cessation. Serum creatine kinase (CK) levels ranged from 2,700 to 16,200 IU/L. EMG was consistent with a myopathic picture. Muscle biopsies revealed a pauci-immune necrotizing myopathy. Detailed graphical representation of the clinical course of these patients showed a close association with rising CK and an increase in clinical weakness signifying relapses, particularly upon weaning or ceasing steroids. All 6 patients were responsive to initial steroid therapy, with 5 relapsing upon attempts to wean steroids. Both CK and clinical strength improved with the reinstitution of immunotherapy, in particular steroids and IV immunoglobulin (IVIg). All patients required treatment with varying multiagent immunosuppressive regimens to achieve clinical remission, including prednisone (n = 6), IVIg (n = 5), plasmapheresis (n = 2), and additional therapy including methotrexate (n = 6), cyclophosphamide (n = 2), rituximab (n = 2), azathioprine (n = 1), and cyclosporine (n = 1). Conclusions: Recognition of HMGCR antibody–associated NAM is important because these patients are responsive to immunosuppression, and early multiagent therapy and a slow and cautious approach to withdrawing steroids may improve outcomes.

1 September 2000 in Journal of Autoimmunity
Verified
Journal Article
Closed access
SRStephen W Reddel
Stephen W Reddel
YWYing Xia Wang
Ying Xia Wang
YSYong Hua Sheng
Yong Hua Sheng
SKSteven A Krilis
Steven A Krilis

31 August 2010 in The Journal of Physiology
Verified
Journal Article
Closed access
RCR. N. Cole
R. N. Cole
NGN. Ghazanfari
N. Ghazanfari
Shyuan T. NgoShyuan T. Ngo
Shyuan T. Ngo
OGO. L. Gervásio
O. L. Gervásio
SRS. W. Reddel
S. W. Reddel
WPW. D. Phillips
W. D. Phillips